Publications

5891 Results

SWOG 1318: Combination of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: Longer Follow up and Predictors of Outcomes

Authors
A Advani;A Moseley;K O'Dwyer;C Yeung;O Sala-Torra;B Wood;J Park;M Wieduwilt;D Jeyakumar;G Yaghmour;E Atallah;A Gerds;S O'Brien;J Liesveld;M Othus;M Litzow;R Stone;J Radich;H Erba
Journal / Conference
ASH Annual Meeting (December 6-9, 2025, Orlando, FL). Abstract 3343 poster. Blood (2025) 146 (Supplement 1): 3343
Year
2025
Research Committee(s)
Leukemia
Study Number(s)
S1318

Development and Validation of a Gene Expression Signature to Predict Early Events in Patients with Follicular Lymphoma

Authors
C Ramsower;G Wright;H Li;J Cerhan;M Mauer;R Mwangi;A Rosenthal;A Novak;B Link;T Witzig;T Habermann;R Kridel;M LeBlanc;M Shadman;S Smith;J Friedberg;D Scott;C Steidl;L Staudt;L Rimsza
Journal / Conference
Blood Advances 2025 Dec 23;9(24):6443-6454. doi: 10.1182/bloodadvances.2025016827.
Year
2025
Research Committee(s)
Lymphoma
PMID
40966421
PMC
PMC12755980
Study Number(s)
S0016

Clinical Trial of Docetaxel with Androgen Receptor Pathway Inhibitors for Metastatic Castration-Sensitive Prostate Cancer Patients with a Suboptimal PSA Response

Authors
A Sokolova;M Ong;S Hotte;T Dorff;K Chi;A Wyatt;A Goldkorn;M Kolinsky;M Brundage;A Ndika;S Lerner;W Parulekar;K Ding;M Jafri
Journal / Conference
Prostate Cancer Foundation annual meeting (October 23-25, 2025, Carlsbad, CA)
Year
2025
Research Committee(s)
Genitourinary
Study Number(s)
CCTG-PR26

Breastfeeding after hormone-receptor positive breast cancer: results from the POSITIVE trial

Authors
F Peccatori
Journal / Conference
Journal of Clinical Oncology, 2025 Aug 20;43(24):2712-2719. doi: 10.1200/JCO-24-02697. Epub 2025 Jul 9.
Year
2025
Research Committee(s)
Cancer Survivorship
PMID
40632989
Study Number(s)
CTSU/A221405

Development and Validation of a Risk Prediction Model for Acute Care Use Among Older Patients with Advanced Cancer on Clinical Trials

Authors
D Hershman;C Till;M LeBlanc;S Ramsey;J Unger
Journal / Conference
JNCI-Journal of the National Cancer Institute djaf342; publ Dec 4, 2025; 10.1093/jnci/djaf342
Year
2025
Research Committee(s)
Cancer Care Delivery

Neoadjuvant PD-1 blockade in patients with surgically resectable desmoplastic 3 melanoma (SWOG S1512 cohort A)

Authors
K Kendra;S Bellasea;Z Eroglu;S Hu-Lieskovan;K Campbell;W Carson;D Wada;J Plaza;G In;A Ikeguchi;J Hyngstrom;A Brohl;B Chmielowski;N Khushalani;J Markowitz;M Monroe;C Contreras;E Medina;C Gonzalez;I Baselga Carretero;I Perez Garcilazo;A Vega-Crespo;J Ming Chen;N Naser Al Deen;S Patel;K Grossmann;V Sondak;E Sharon;J Moon;M Wu;A Ribas
Journal / Conference
Nature Cancer. 2026 Feb;7(2):272-282. doi: 10.1038/s43018-025-01113-y. Epub 2026 Jan 29.
Year
2025
Research Committee(s)
Melanoma
PMID
41611998
PMC
PMC12948668
Study Number(s)
S1512

Endpoint and design considerations for a randomized comparison of neoadjuvant-adjuvant versus adjuvant-only cancer immunotherapy (SWOG S1801)

Authors
M Othus;E Sharon;M Wu;V Sondak;A Ribas;S Patel
Journal / Conference
Sage Journals 2025 Oct;22(5):571-577. doi: 10.1177/17407745251321371. Epub 2025 Mar 18. PMID: 40099861; PMCID: PMC12353050.
Year
2025
Research Committee(s)
Melanoma
PMID
40099861
PMC
PMC12353050
Study Number(s)
S1801

Development and validation of a novel conditional event-free survival tool in diffuse large B-cell lymphoma

Authors
Z Chen;D Luan;R Rask;L Jakobsen;M Maurer;T El-Galaly;L Nastoupil;J Cerhan;C Flowers;B Link;I Lossos;D Stephens;J Cohen;J Habermann;G Nowakowski;N Bartlett;J Friedberg;B Kahl;J Leonard;P Brown;K Smedby;M Jerkeman;P Martin
Journal / Conference
Journal of Clinical Oncology
Year
2025
Research Committee(s)
Lymphoma
Study Number(s)
S1001

Clinical and molecular characterization of AXL in colorectal cancer, CALGB (Alliance)/SWOG 80405 and real-world data

Authors
Ashouri K
Journal / Conference
Journal for ImmunoTherapy of Cancer. 2025 Dec 21; 13: e013186. DOI: 10.1136/jitc-2025-013186.
Year
2025
Research Committee(s)
Gastrointestinal
PMID
PMID41423272
Study Number(s)
CTSU/C80405

Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201

Authors
Kam AE
Journal / Conference
Oncologist. 2025 Dec 27; 31: oyaf416. DOI: 10.1093/oncolo/oyaf416.
Year
2025
Research Committee(s)
Gastrointestinal
PMID
PMID41397917
Study Number(s)
CTSU/E3201